Loading ...
by other steroid drugs(passive) caused byaromatization adverse events
drug , device , or dietary supplementcausedadverse event
When researchers excluded patients who received folic acid supplementation , both polymorphisms ( 2R/3R repeat and 6 bp deletion ) appearedto influenceadverse events occurrence
vaccinecausingadverse event
by vaccine(passive) was causedadverse event
by the study drug 6(passive) caused byadverse event
any drugcausingADVERSE EVENT
drugcausedadverse event
by medical management ( rather than the underlying disease(passive) was caused byAdverse event
by patient conditions(passive) caused byAdverse event
by a medicine(passive) is ... causedadverse event
other drugscauseADVERSE EVENT
DrugscausedAdverse Event
FOSAMAX ... other drugscauseADVERSE EVENT
NEXIUM ... other drugscauseADVERSE EVENT
COZAAR ... other drugscauseADVERSE EVENT
by data errors(passive) caused byadverse event
medical errors(passive) caused byAvoidable adverse events
The drug was knownto causeneuropsychiatric adverse events
PAXIL with other drugscauseADVERSE EVENT
ASPIRIN ... other drugscauseADVERSE EVENT
ACETAMINOPHEN ... other drugscauseADVERSE EVENT
XARELTO ... other drugscauseADVERSE EVENT
DIGOXIN ... other drugscauseADVERSE EVENT
ISOTRETINOIN ... other drugscauseADVERSE EVENT
THALIDOMIDE ... other drugscauseADVERSE EVENT
the most common procedurecausesadverse event
a possibilitycould causeAdverse Event
THERAPYcausesADVERSE EVENT
by LOPERAMIDE , including potential interactions with other medications(passive) caused byadverse events
by such product(passive) caused byunanticipated adverse events
by prolonged use of drugs and many drug - drug interactions(passive) caused byadverse events
by the study medication or treatment(passive) to be caused byadverse events
systemic administration of drugscausesadverse events
by potential drug - drug interactions(passive) caused byAdverse events
their drugto causeneurocognitive adverse events
a number of things , including an allergic reaction , side effects , or interactions between medications , smoking , or other things ( e.g. , supplements or recreational drugs(passive) can be caused byadverse events
by inappropriate care or other factors(passive) caused byadverse events
the health care systems in which patients receive care(passive) can be ... influenced byadverse events
the risk for potential medication related errorsmay causeadverse events
death or serious disabilitycauseddeath or serious disability
in harm to patientshave ... resultedin harm to patients
to the death of 210,000 - 400,000 patients who seek care at a hospitalleadto the death of 210,000 - 400,000 patients who seek care at a hospital
in actual injuryresultin actual injury
in unintended outcomes for patients as a result of clinical interventions or omissions , or the systems or processes used in managing patient careresultin unintended outcomes for patients as a result of clinical interventions or omissions , or the systems or processes used in managing patient care
to dose reduction of the study drug in 24 % vs 1 % and discontinuation of treatment in 22 % vs 5 %ledto dose reduction of the study drug in 24 % vs 1 % and discontinuation of treatment in 22 % vs 5 %
to severe disability and neonatal mortalityleadingto severe disability and neonatal mortality
to a dose reduction in 16 % of patients , dose interruption in 19 % , and permanent treatment discontinuation in 11 %ledto a dose reduction in 16 % of patients , dose interruption in 19 % , and permanent treatment discontinuation in 11 %
to dose reduction in 12 % vs 11 % of patients and to treatment discontinuation in 7 % vs 7 %ledto dose reduction in 12 % vs 11 % of patients and to treatment discontinuation in 7 % vs 7 %
to dose interruption in 25 % vs 24 % , dose reduction in 4 % vs 5 % , and discontinuation of treatment in 13 % vs 18 %ledto dose interruption in 25 % vs 24 % , dose reduction in 4 % vs 5 % , and discontinuation of treatment in 13 % vs 18 %
to dose reduction / interruption in 21 % of patients and to treatment discontinuation in 8 %ledto dose reduction / interruption in 21 % of patients and to treatment discontinuation in 8 %
to permanent discontinuation of study treatment in 13 % of combination patientsledto permanent discontinuation of study treatment in 13 % of combination patients
to dose reduction in 6 % of patients and treatment discontinuation in 13 %ledto dose reduction in 6 % of patients and treatment discontinuation in 13 %
to dose reduction of any drug in 56 % vs 50 % , discontinuation of any drug in 25 % vs 20 % , and discontinuation of the study regimen in 17 % vs 14 %ledto dose reduction of any drug in 56 % vs 50 % , discontinuation of any drug in 25 % vs 20 % , and discontinuation of the study regimen in 17 % vs 14 %
to dose reduction in 17 % of patients and treatment discontinuation in 7 %ledto dose reduction in 17 % of patients and treatment discontinuation in 7 %
to dose interruptions in 56 % vs 36 % of patients , dose reductions in 35 % vs 17 % , and treatment discontinuation in 14 % vs 11 %ledto dose interruptions in 56 % vs 36 % of patients , dose reductions in 35 % vs 17 % , and treatment discontinuation in 14 % vs 11 %
to discontinuationleadingto discontinuation
to dose reductions in 45 % vs 3 % of patients and to discontinuation of treatment in 7 % vs 2 %ledto dose reductions in 45 % vs 3 % of patients and to discontinuation of treatment in 7 % vs 2 %
to discontinuation of treatment with the study drug ( 7 % vs 7 %leadingto discontinuation of treatment with the study drug ( 7 % vs 7 %
to dose interruption or reduction in 37 % and permanent treatment discontinuation in 13 %ledto dose interruption or reduction in 37 % and permanent treatment discontinuation in 13 %
to dose reduction in 3 % and treatment discontinuation in 5 % ( due to pneumonitis in 2 patientsledto dose reduction in 3 % and treatment discontinuation in 5 % ( due to pneumonitis in 2 patients
to treatment interruption in 19 % vs 25 % , dose reduction in 16 % vs 21 % , and treatment discontinuation in 11 % vs 13 %ledto treatment interruption in 19 % vs 25 % , dose reduction in 16 % vs 21 % , and treatment discontinuation in 11 % vs 13 %
to dose reduction in 34 % of patients and to treatment discontinuation in 12 %ledto dose reduction in 34 % of patients and to treatment discontinuation in 12 %
dose interruption in 57 % of patients , dose reduction in 38 % , and treatment discontinuation in 19 %causeddose interruption in 57 % of patients , dose reduction in 38 % , and treatment discontinuation in 19 %
to dose reduction in 37 % of patients and discontinuation of treatment in 10 %ledto dose reduction in 37 % of patients and discontinuation of treatment in 10 %
to withdrawal from treatment ( discontinuation of trial drug or withdrawal from trialleadingto withdrawal from treatment ( discontinuation of trial drug or withdrawal from trial
to discontinuation of treatment or withdrawal from the trial in 6 % of the triple - therapy groupledto discontinuation of treatment or withdrawal from the trial in 6 % of the triple - therapy group
to dose reduction or study drug discontinuation inleadingto dose reduction or study drug discontinuation in
to a dose reduction or study drug discontinuationledto a dose reduction or study drug discontinuation
to study drug discontinuation in more patients in the bevacizumab groupledto study drug discontinuation in more patients in the bevacizumab group
to the discontinuation of the study drug ( for patients in the evolocumab groupleadingto the discontinuation of the study drug ( for patients in the evolocumab group
to dose reduction in 6 % of patients and treatment discontinuation in 13 % , with discontinuation being due to renal events in five patients ( 4.5 % ) and hematologic toxicity in four patients ( 3.6 %ledto dose reduction in 6 % of patients and treatment discontinuation in 13 % , with discontinuation being due to renal events in five patients ( 4.5 % ) and hematologic toxicity in four patients ( 3.6 %
to discontinuation of treatment with the study drugleadingto discontinuation of treatment with the study drug
to dose reduction in 25 % vs 13 % , interruption in 49 % vs 33 % , and discontinuation in 9 % vs 5 % of patientsledto dose reduction in 25 % vs 13 % , interruption in 49 % vs 33 % , and discontinuation in 9 % vs 5 % of patients
to permanent discontinuation of study drug n ( % ) of patients ( Safety populationleadingto permanent discontinuation of study drug n ( % ) of patients ( Safety population
to dose reduction in 22 % vs 2 % , dose interruption in 22 % vs 7 % , and discontinuation of treatment in 30 % vs 5 %ledto dose reduction in 22 % vs 2 % , dose interruption in 22 % vs 7 % , and discontinuation of treatment in 30 % vs 5 %
to treatment discontinuation or study withdrawalleadingto treatment discontinuation or study withdrawal
to dose modification or interruption in 32 % vs 17 % and to treatment discontinuation in 12 % vs 10 %ledto dose modification or interruption in 32 % vs 17 % and to treatment discontinuation in 12 % vs 10 %
to discontinuation of treatment in no more than 1 % of patients in any treatment groupledto discontinuation of treatment in no more than 1 % of patients in any treatment group
to discontinuation of trial treatment or dose reductionleadingto discontinuation of trial treatment or dose reduction